TGA approves insulin pen swap amid global shortage
Pharmacists have been granted legal permission to dispense Ryzodeg 70/30 Penfill instead of FlexTouch.
The TGA will allow pharmacists to swap out certain pre-filled insulin products in response to a global shortage predicted to last until June 2024.
Ryzodeg 70/30 FlexTouch, a combined insulin degludec, insulin aspart and injector product, is in shortage because of “unprecedented” global demand for different medicines using the same FlexTouch injector, the TGA says.
As a result, it has granted pharmacists legal permission to dispense Ryzodeg 70/30 Penfill, another Novo Nordisk product, instead of FlexTouch.
The products are equal in strength and both subcutaneously injected, but the substitute product does not include an injector.
